CN Patent

CN117561334A — 人染色体9开放阅读框72（C9ORF72）iRNA药剂组合物和其使用方法

Assigned to Regeneron Pharmaceuticals Inc · Expires 2024-02-13 · 2y expired

What this patent protects

本公开涉及靶向人染色体9开放阅读框72(C9orf72)基因的双链核糖核酸(dsRNAi)药剂和组合物以及使用此类dsRNAi药剂和组合物来抑制C9orf72基因的表达的方法和治疗患有C9orf72相关疾病或病症，例如，C9orf72肌萎缩性侧索硬化症、额颞叶痴呆或由于C9orf72扩增引起的亨廷顿样综合征(Huntington‑Like Syndrome)的受试者的方法。

USPTO Abstract

本公开涉及靶向人染色体9开放阅读框72(C9orf72)基因的双链核糖核酸(dsRNAi)药剂和组合物以及使用此类dsRNAi药剂和组合物来抑制C9orf72基因的表达的方法和治疗患有C9orf72相关疾病或病症，例如，C9orf72肌萎缩性侧索硬化症、额颞叶痴呆或由于C9orf72扩增引起的亨廷顿样综合征(Huntington‑Like Syndrome)的受试者的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117561334A
Jurisdiction
CN
Classification
—
Expires
2024-02-13
Drug substance claim
No
Drug product claim
No
Assignee
Regeneron Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.